{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:11:35Z","timestamp":1793531495048,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04393-7","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:27:02Z","timestamp":1755998822000},"page":"439-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3584-6212","authenticated-orcid":false,"given":"Beema T","family":"Yoosuf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-6839","authenticated-orcid":false,"given":"Muhammed Favas","family":"KT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spoorthy","family":"D P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasar","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Medenica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-3293","authenticated-orcid":false,"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"issue":"5","key":"4393_CR1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","volume":"24","author":"R Pishdad","year":"2024","unstructured":"R. Pishdad, P.G. Auwaerter, R.R. Kalyani, Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review. Curr. Diab. Rep. 24(5), 108\u2013117 (2024).","journal-title":"Curr. Diab. Rep."},{"issue":"13","key":"4393_CR2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","volume":"107","author":"SS Joshi","year":"2021","unstructured":"S.S. Joshi, T. Singh, D.E. Newby, J. Singh, Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart 107(13), 1032\u20131038 (2021).","journal-title":"Heart"},{"issue":"1","key":"4393_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","volume":"21","author":"B Xu","year":"2022","unstructured":"B. Xu, S. Li, B. Kang, J. Zhou, The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc. Diabetol. 21(1), 83 (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"4393_CR4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"17","author":"RA DeFronzo","year":"2021","unstructured":"R.A. DeFronzo, W.B. Reeves, A.S. Awad, Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 17(5), 319\u2013334 (2021).","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"4393_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"E. Ferrannini, Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26(1), 27\u201338 (2017).","journal-title":"Cell Metab."},{"issue":"1","key":"4393_CR6","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","volume":"8","author":"AP McGovern","year":"2020","unstructured":"A.P. McGovern, M. Hogg, B.M. Shields, N.A. Sattar, R.R. Holman, E.R. Pearson et al., Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open. Diabetes Res. Care 8(1), e001238 (2020).","journal-title":"BMJ Open. Diabetes Res. Care"},{"issue":"8","key":"4393_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"E. Ferrannini, A. Solini, SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol. 8(8), 495\u2013502 (2012).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"4393_CR8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"F. Zaccardi, D.R. Webb, Z.Z. Htike, D. Youssef, K. Khunti, M.J. Davies, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes. Metab. 18(8), 783\u2013794 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"4393_CR9","unstructured":"NICE guideline on type 2 diabetes in adults: management (2022), https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093. Accessed 7 Feb 2023"},{"issue":"6","key":"4393_CR10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcjd.2016.09.003","volume":"40","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2016","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Pharmacologic management of type 2 diabetes: 2016 interim update. Can. J. Diabetes 40(6), 484\u2013486 (2016).","journal-title":"Can. J. Diabetes"},{"issue":"Suppl 1","key":"4393_CR11","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee, 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1), S125\u2013s43 (2022).","journal-title":"Diabetes Care"},{"key":"4393_CR12","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (2015), https:\/\/www.fda.gov\/files\/drugs\/published\/FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections.pdf"},{"issue":"3","key":"4393_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"S. Geerlings, V. Fonseca, D. Castro-Diaz, J. List, S. Parikh, Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103(3), 373\u2013381 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"11","key":"4393_CR14","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"I.C. Lega, S.E. Bronskill, M.A. Campitelli, J. Guan, N.M. Stall, K. Lam et al., Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes. Metab. 21(11), 2394\u20132404 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4393_CR15","volume":"7","author":"J Liu","year":"2017","unstructured":"J. Liu, L. Li, S. Li, P. Jia, K. Deng, W. Chen et al., Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci. Rep. 7(1), 2824 (2017).","journal-title":"Sci. Rep."},{"issue":"5","key":"4393_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"R. Puckrin, M.P. Saltiel, P. Reynier, L. Azoulay, O.H.Y. Yu, K.B. Filion, SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55(5), 503\u2013514 (2018).","journal-title":"Acta Diabetol."},{"issue":"11","key":"4393_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"B. Hutton, G. Salanti, D.M. Caldwell, A. Chaimani, C.H. Schmid, C. Cameron et al., The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"key":"4393_CR18","doi-asserted-by":"crossref","unstructured":"J.P. Higgins, J.Savovi\u0107, M.J. Page, R.G. Elbers, J.A. Sterne, Assessing risk of bias in a randomized trial. In: J.P.T. Higgins, J.Thomas, J.Chandler, M.Cumpston, Li T, M.J.Page, V.A. Welch, eds. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019. p. 205-228.","DOI":"10.1002\/9781119536604.ch8"},{"issue":"7414","key":"4393_CR19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327(7414), 557\u2013560 (2003).","journal-title":"BMJ"},{"key":"4393_CR20","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard, https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis Accessed June 2024."},{"key":"4393_CR21","unstructured":"OpenVigil 2.1-MedDRA-v24 (2004Q1-2024Q2), https:\/\/openvigil.sourceforge.net\/ Accessed June 2024."},{"key":"4393_CR22","doi-asserted-by":"crossref","unstructured":"Bansal D, Yoosuf BT, Favas MK. Role of medical coding in signal detection. In: Kumar A, editor. Signal analysis in pharmacovigilance: principles and processes. Boca Raton (FL): CRC Press; 2024. p. 95-110.","DOI":"10.1201\/9781032629940-6"},{"issue":"6","key":"4393_CR23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"S.J. Evans, P.C. Waller, S. Davis, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug. Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"4393_CR24","doi-asserted-by":"crossref","unstructured":"Bansal D, Yoosuf BT, Favas MK. Bayesian methods of signal detection. In: Kumar A, editor. Signal analysis in pharmacovigilance: principles and processes. Boca Raton (FL): CRC Press; 2024. p. 135-147.","DOI":"10.1201\/9781032629940-9"},{"issue":"22","key":"4393_CR25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"4393_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn et al., Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347\u2013357 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"4393_CR27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/dom.12047","volume":"15","author":"K Kaku","year":"2013","unstructured":"K. Kaku, S. Inoue, O. Matsuoka, A. Kiyosue, H. Azuma, N. Hayashi et al., Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 15(5), 432\u2013440 (2013).","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"4393_CR28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/dom.13981","volume":"22","author":"T Vilsb\u00f8ll","year":"2020","unstructured":"T. Vilsb\u00f8ll, E. Ekholm, E. Johnsson, R. Garcia-Sanchez, N. Dronamraju, S.A. Jabbour et al., Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52\u2009weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: a randomized, parallel-design, open-label, Phase 3 trial. Diabetes Obes. Metab. 22(6), 957\u2013968 (2020).","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"4393_CR29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13152","volume":"20","author":"N Inagaki","year":"2018","unstructured":"N. Inagaki, S.I. Harashima, K. Kaku, K. Kondo, N. Maruyama, M. Otsuka et al., Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 20(4), 812\u2013820 (2018).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"4393_CR30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"T. Forst, R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab. 16(5), 467\u2013477 (2014).","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"4393_CR31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"J.F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 16(10), 1016\u20131027 (2014).","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"4393_CR32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dom.13909","volume":"22","author":"H Sone","year":"2020","unstructured":"H. Sone, T. Kaneko, K. Shiki, Y. Tachibana, E. Pfarr, J. Lee et al., Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 22(3), 417\u2013426 (2020).","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"4393_CR33","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/dom.13681","volume":"21","author":"L Ji","year":"2019","unstructured":"L. Ji, Y. Liu, H. Miao, Y. Xie, M. Yang, W. Wang et al., Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes. Metab. 21(6), 1474\u20131482 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"4393_CR34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","volume":"15","author":"E Ferrannini","year":"2013","unstructured":"E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, H.J.A. Woerle, Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes. Metab. 15(8), 721\u2013728 (2013).","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"4393_CR35","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/dom.14385","volume":"23","author":"I Lingvay","year":"2021","unstructured":"I. Lingvay, M. Greenberg, S. Gallo, H. Shi, J. Liu, I. Gantz, Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: a VERTIS CV substudy. Diabetes Obes. Metab. 23(7), 1640\u20131651 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4393_CR36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/dom.14259","volume":"23","author":"J Bae","year":"2021","unstructured":"J. Bae, J.H. Huh, M. Lee, Y.H. Lee, B.W. Lee, Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: a 24-week, randomized controlled trial. Diabetes Obes. Metab. 23(2), 609\u2013618 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"4393_CR37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"R.E. Pratley, R. Eldor, A. Raji, G. Golm, S.B. Huyck, Y. Qiu et al., Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes. Metab. 20(5), 1111\u20131120 (2018).","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"4393_CR38","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/dom.13795","volume":"21","author":"J Rosenstock","year":"2019","unstructured":"J. Rosenstock, S. Perl, E. Johnsson, R. Garc\u00eda-S\u00e1nchez, S. Jacob, Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obes. Metab. 21(9), 2152\u20132162 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"4393_CR39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"S. Gallo, B. Charbonnel, A. Goldman, H. Shi, S. Huyck, A. Darekar et al., Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes. Metab. 21(4), 1027\u20131036 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"4393_CR40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dom.12460","volume":"17","author":"NB Amin","year":"2015","unstructured":"N.B. Amin, X. Wang, S.M. Jain, D.S. Lee, G. Nucci, J.M. Rusnak, Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes. Metab. 17(6), 591\u2013598 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"4393_CR41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","volume":"20","author":"J Rosenstock","year":"2018","unstructured":"J. Rosenstock, J. Frias, D. P\u00e1ll, B. Charbonnel, R. Pascu, D. Saur et al., Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes. Metab. 20(3), 520\u2013529 (2018).","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"4393_CR42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"J.P. Wilding, G. Charpentier, P. Hollander, G. Gonz\u00e1lez-G\u00e1lvez, C. Mathieu, F. Vercruysse et al., Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int. J. Clin. Pract. 67(12), 1267\u20131282 (2013).","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"4393_CR43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"K. Stenl\u00f6f, W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong et al., Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 15(4), 372\u2013382 (2013).","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4393_CR44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","volume":"16","author":"JP Wilding","year":"2014","unstructured":"J.P. Wilding, V. Woo, K. Rohwedder, J. Sugg, S. Parikh, Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes. Metab. 16(2), 124\u2013136 (2014).","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"4393_CR45","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","volume":"14","author":"CJ Bailey","year":"2012","unstructured":"C.J. Bailey, N. Iqbal, C. T\u2019Joen, J.F. List, Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes. Metab. 14(10), 951\u2013959 (2012).","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"4393_CR46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"K. Strojek, K.H. Yoon, V. Hruba, M. Elze, A.M. Langkilde, S. Parikh, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 13(10), 928\u2013938 (2011).","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"4393_CR47","volume":"47","author":"SC Liu","year":"2021","unstructured":"S.C. Liu, C.C. Lee, S.M. Chuang, F.J. Sun, Y.H. Zeng, Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: a randomized, open-label study. Diabetes Metab. 47(3), 101184 (2021).","journal-title":"Diabetes Metab."},{"issue":"2","key":"4393_CR48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","volume":"41","author":"B Bode","year":"2013","unstructured":"B. Bode, K. Stenl\u00f6f, D. Sullivan, A. Fung, K. Usiskin, Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp. Pract. 41(2), 72\u201384 (2013).","journal-title":"Hosp. Pract."},{"issue":"2","key":"4393_CR49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"C.S. Kovacs, V. Seshiah, R. Swallow, R. Jones, H. Rattunde, H.J. Woerle et al., Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes. Metab. 16(2), 147\u2013158 (2014).","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"4393_CR50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","volume":"20","author":"S Dagogo-Jack","year":"2018","unstructured":"S. Dagogo-Jack, J. Liu, R. Eldor, G. Amorin, J. Johnson, D. Hille et al., Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes. Metab. 20(3), 530\u2013540 (2018).","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"4393_CR51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"C.J. Bailey, E.C. Morales Villegas, V. Woo, W. Tang, A. Ptaszynska, J.F. List, Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet. Med. 32(4), 531\u2013541 (2015).","journal-title":"Diabet. Med."},{"issue":"1","key":"4393_CR52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/dom.12589","volume":"18","author":"G Fulcher","year":"2016","unstructured":"G. Fulcher, D.R. Matthews, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, C. Mathieu et al., Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 18(1), 82\u201391 (2016).","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"4393_CR53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","volume":"17","author":"S Del Prato","year":"2015","unstructured":"S. Del Prato, M. Nauck, S. Dur\u00e1n-Garcia, L. Maffei, K. Rohwedder, A. Theuerkauf et al., Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes. Metab. 17(6), 581\u2013590 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"4393_CR54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/dom.13594","volume":"21","author":"Y Handelsman","year":"2019","unstructured":"Y. Handelsman, C. Mathieu, S. Del Prato, E. Johnsson, R. Kurlyandskaya, N. Iqbal et al., Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes. Metab. 21(4), 883\u2013892 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"4393_CR55","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"J. Rosenstock, L.J. Seman, A. Jelaska, S. Hantel, S. Pinnetti, T. Hach et al., Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes. Metab. 15(12), 1154\u20131160 (2013).","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4393_CR56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/dom.12385","volume":"17","author":"L Ji","year":"2015","unstructured":"L. Ji, P. Han, Y. Liu, G. Yang, N.K. Dieu Van, U. Vijapurkar et al., Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes. Metab. 17(1), 23\u201331 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"4393_CR57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","volume":"18","author":"HW Rodbard","year":"2016","unstructured":"H.W. Rodbard, J. Seufert, N. Aggarwal, A. Cao, A. Fung, M. Pfeifer et al., Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes. Metab. 18(8), 812\u2013819 (2016).","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"4393_CR58","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/dom.12898","volume":"19","author":"T Kadowaki","year":"2017","unstructured":"T. Kadowaki, N. Inagaki, K. Kondo, K. Nishimura, G. Kaneko, N. Maruyama et al., Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 19(6), 874\u2013882 (2017).","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"4393_CR59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"J. Rosenstock, A. Jelaska, C. Zeller, G. Kim, U.C. Broedl, H.J. Woerle, Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 17(10), 936\u2013948 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"4393_CR60","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/dme.12814","volume":"32","author":"L Merker","year":"2015","unstructured":"L. Merker, H.U. H\u00e4ring, A.V. Christiansen, F. Roux, A. Salsali, G. Kim et al., Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet. Med. 32(12), 1555\u20131567 (2015).","journal-title":"Diabet. Med."},{"issue":"12","key":"4393_CR61","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"F.J. Lavalle-Gonz\u00e1lez, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, W. Canovatchel et al., Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12), 2582\u20132592 (2013).","journal-title":"Diabetologia"},{"key":"4393_CR62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","volume":"15","author":"N Inagaki","year":"2016","unstructured":"N. Inagaki, S. Harashima, N. Maruyama, Y. Kawaguchi, M. Goda, H. Iijima, Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 15, 89 (2016).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"4393_CR63","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","volume":"66","author":"RR Henry","year":"2012","unstructured":"R.R. Henry, A.V. Murray, M.H. Marmolejo, D. Hennicken, A. Ptaszynska, J.F. List, Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 66(5), 446\u2013456 (2012).","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"4393_CR64","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","volume":"19","author":"SG Terra","year":"2017","unstructured":"S.G. Terra, K. Focht, M. Davies, J. Frias, G. Derosa, A. Darekar et al., Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes. Metab. 19(5), 721\u2013728 (2017).","journal-title":"Diabetes Obes. Metab."},{"issue":"9733","key":"4393_CR65","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, J.F. List, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733), 2223\u20132233 (2010).","journal-title":"Lancet"},{"issue":"6","key":"4393_CR66","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","volume":"8","author":"W Yang","year":"2016","unstructured":"W. Yang, P. Han, K.W. Min, B. Wang, T. Mansfield, C. T\u2019Joen et al., Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J. Diabetes 8(6), 796\u2013808 (2016).","journal-title":"J. Diabetes"},{"issue":"6","key":"4393_CR67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"J.P. Wilding, V. Woo, N.G. Soler, A. Pahor, J. Sugg, K. Rohwedder et al., Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann. Intern. Med. 156(6), 405\u2013415 (2012).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"4393_CR68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/03007995.2017.1405800","volume":"34","author":"KC Ferdinand","year":"2018","unstructured":"K.C. Ferdinand, L. Seman, A. Salsali, Design of a 24-week trial of empagliflozin once daily in hypertensive black\/African American patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 34(2), 361\u2013367 (2018).","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"4393_CR69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"I. Lingvay, A.M. Catarig, J.P. Frias, H. Kumar, N.L. Lausvig, C.W. le Roux et al., Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 7(11), 834\u2013844 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"4393_CR70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"J.P. Fr\u00edas, C. Guja, E. Hardy, A. Ahmed, F. Dong, P. \u00d6hman et al., Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 4(12), 1004\u20131016 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"4393_CR71","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/dia.2018.0052","volume":"20","author":"RR Henry","year":"2018","unstructured":"R.R. Henry, P. Strange, R. Zhou, J. Pettus, L. Shi, S.B. Zhuplatov et al., Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Technol. Ther. 20(11), 715\u2013724 (2018).","journal-title":"Diabetes Technol. Ther."},{"issue":"6","key":"4393_CR72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"C. Pollock, B. Stef\u00e1nsson, D. Reyner, P. Rossing, C.D. Sj\u00f6str\u00f6m, D.C. Wheeler et al., Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 7(6), 429\u2013441 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4393_CR73","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"C.J. Bailey, J.L. Gross, D. Hennicken, N. Iqbal, T.A. Mansfield, J.F. List, Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 11, 43 (2013).","journal-title":"BMC Med."},{"issue":"9","key":"4393_CR74","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstr\u00e5le","year":"2014","unstructured":"M. Ridderstr\u00e5le, K.R. Andersen, C. Zeller, G. Kim, H.J. Woerle, U.C. Broedl, Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2(9), 691\u2013700 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9896","key":"4393_CR75","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Niskanen, J. Xie et al., Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896), 941\u2013950 (2013).","journal-title":"Lancet"},{"issue":"15","key":"4393_CR76","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"C.P. Cannon, R. Pratley, S. Dagogo-Jack, J. Mancuso, S. Huyck, U. Masiukiewicz et al., Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383(15), 1425\u20131435 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"4393_CR77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdi.12453","volume":"7","author":"E Araki","year":"2016","unstructured":"E. Araki, Y. Onishi, M. Asano, H. Kim, E. Ekholm, E. Johnsson et al., Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J. Diabetes Investig. 7(4), 555\u2013564 (2016).","journal-title":"J. Diabetes Investig."},{"issue":"7","key":"4393_CR78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1753-0407.12634","volume":"10","author":"W Yang","year":"2018","unstructured":"W. Yang, J. Ma, Y. Li, Y. Li, Z. Zhou, J.H. Kim et al., Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J. Diabetes 10(7), 589\u2013599 (2018).","journal-title":"J. Diabetes"},{"key":"4393_CR79","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"M. Roden, L. Merker, A.V. Christiansen, F. Roux, A. Salsali, G. Kim et al., Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc. Diabetol. 14, 154 (2015).","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"4393_CR80","first-page":"188","volume":"33","author":"M Babar","year":"2021","unstructured":"M. Babar, M. Hussain, M. Ahmad, L. Akhtar, Comparison of efficacy and safety profile of empagliflozin as a combination therapy in obese type 2 diabetic patients. J. Ayub Med. Coll. Abbottabad 33(2), 188\u2013191 (2021).","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"issue":"24","key":"4393_CR81","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"V. Perkovic, M.J. Jardine, B. Neal, S. Bompoint, H.J.L. Heerspink, D.M. Charytan et al., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"4393_CR82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"M. Roden, J. Weng, J. Eilbracht, B. Delafont, G. Kim, H.J. Woerle et al., Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 1(3), 208\u2013219 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"4393_CR83","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"J. Bolinder, \u00d6 Ljunggren, J. Kullberg, L. Johansson, J. Wilding, A.M. Langkilde et al., Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97(3), 1020\u20131031 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4393_CR84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","volume":"25","author":"MA Weber","year":"2016","unstructured":"M.A. Weber, T.A. Mansfield, F. Alessi, N. Iqbal, S. Parikh, A. Ptaszynska, Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 25(2), 93\u2013103 (2016).","journal-title":"Blood Press."},{"issue":"1","key":"4393_CR85","doi-asserted-by":"crossref","first-page":"e002484","DOI":"10.1136\/bmjdrc-2021-002484","volume":"9","author":"S Dagogo-Jack","year":"2021","unstructured":"S. Dagogo-Jack, R.E. Pratley, D.Z.I. Cherney, D.K. McGuire, F. Cosentino, W.J. Shih et al., Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open. Diabetes Res. Care 9(1), e002484 (2021).","journal-title":"BMJ Open. Diabetes Res. Care"},{"issue":"6","key":"4393_CR86","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","volume":"31","author":"T Kadowaki","year":"2014","unstructured":"T. Kadowaki, M. Haneda, N. Inagaki, Y. Terauchi, A. Taniguchi, K. Koiwai et al., Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv. Ther. 31(6), 621\u2013638 (2014).","journal-title":"Adv. Ther."},{"issue":"9","key":"4393_CR87","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"M.A. Nauck, S. Del Prato, J.J. Meier, S. Dur\u00e1n-Garc\u00eda, K. Rohwedder, M. Elze et al., Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34(9), 2015\u20132022 (2011).","journal-title":"Diabetes Care"},{"issue":"10","key":"4393_CR88","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"SA Jabbour","year":"2018","unstructured":"S.A. Jabbour, J.P. Fr\u00edas, E. Hardy, A. Ahmed, H. Wang, P. \u00d6hman et al., Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 41(10), 2136\u20132146 (2018).","journal-title":"Diabetes Care"},{"issue":"2","key":"4393_CR89","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","volume":"30","author":"K Stenl\u00f6f","year":"2014","unstructured":"K. Stenl\u00f6f, W.T. Cefalu, K.A. Kim, E. Jodar, M. Alba, R. Edwards et al., Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr. Med. Res. Opin. 30(2), 163\u2013175 (2014).","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"4393_CR90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","volume":"36","author":"L Ji","year":"2014","unstructured":"L. Ji, J. Ma, H. Li, T.A. Mansfield, C.L. T\u2019Joen, N. Iqbal et al., Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin. Ther. 36(1), 84\u2013100.e9 (2014).","journal-title":"Clin. Ther."},{"issue":"10","key":"4393_CR91","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, J.F. List, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10), 2217\u20132224 (2010).","journal-title":"Diabetes Care"},{"issue":"4","key":"4393_CR92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"J.F. List, V. Woo, E. Morales, W. Tang, F.T. Fiedorek, Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32(4), 650\u2013657 (2009).","journal-title":"Diabetes Care"},{"issue":"10","key":"4393_CR93","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","volume":"43","author":"SA Jabbour","year":"2020","unstructured":"S.A. Jabbour, J.P. Fr\u00edas, A. Ahmed, E. Hardy, J. Choi, C.D. Sj\u00f6str\u00f6m et al., Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43(10), 2528\u20132536 (2020).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR94","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","volume":"38","author":"B Neal","year":"2015","unstructured":"B. Neal, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, G. Fulcher, K. Ways et al., Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38(3), 403\u2013411 (2015).","journal-title":"Diabetes Care"},{"issue":"10","key":"4393_CR95","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","volume":"39","author":"S Hadjadj","year":"2016","unstructured":"S. Hadjadj, J. Rosenstock, T. Meinicke, H.J. Woerle, U.C. Broedl, Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 39(10), 1718\u20131728 (2016).","journal-title":"Diabetes Care"},{"issue":"7","key":"4393_CR96","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"W.T. Cefalu, L.A. Leiter, T.W. de Bruin, I. Gause-Nilsson, J. Sugg, S.J. Parikh, Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38(7), 1218\u20131227 (2015).","journal-title":"Diabetes Care"},{"issue":"8","key":"4393_CR97","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/03007995.2019.1583450","volume":"35","author":"P Hollander","year":"2019","unstructured":"P. Hollander, J. Hill, J. Johnson, Z. Wei Jiang, G. Golm, S. Huyck et al., Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr. Med. Res. Opin. 35(8), 1335\u20131343 (2019).","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"4393_CR98","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1111\/dom.13437","volume":"20","author":"D M\u00fcller-Wieland","year":"2018","unstructured":"D. M\u00fcller-Wieland, M. Kellerer, K. Cypryk, D. Skripova, K. Rohwedder, E. Johnsson et al., Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes. Metab. 20(11), 2598\u20132607 (2018).","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"4393_CR99","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"C. Mathieu, A.E. Ranetti, D. Li, E. Ekholm, W. Cook, B. Hirshberg et al., Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 38(11), 2009\u20132017 (2015).","journal-title":"Diabetes Care"},{"issue":"9","key":"4393_CR100","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"JP Wilding","year":"2009","unstructured":"J.P. Wilding, P. Norwood, C. T\u2019Joen, A. Bastien, J.F. List, F.T. Fiedorek, A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9), 1656\u20131662 (2009).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"J. Rosenstock, L. Chuck, M. Gonz\u00e1lez-Ortiz, K. Merton, J. Craig, G. Capuano et al., Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-na\u00efve type 2 diabetes. Diabetes Care 39(3), 353\u2013362 (2016).","journal-title":"Diabetes Care"},{"issue":"6","key":"4393_CR102","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, K. Usiskin et al., Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35(6), 1232\u20131238 (2012).","journal-title":"Diabetes Care"},{"issue":"9","key":"4393_CR103","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, J. Yee et al., Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36(9), 2508\u20132515 (2013).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR104","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"RA DeFronzo","year":"2015","unstructured":"R.A. DeFronzo, A. Lewin, S. Patel, D. Liu, R. Kaste, H.J. Woerle et al., Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38(3), 384\u2013393 (2015).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"S. Matthaei, K. Bowering, K. Rohwedder, A. Grohl, S. Parikh, Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 38(3), 365\u2013372 (2015).","journal-title":"Diabetes Care"},{"issue":"2","key":"4393_CR106","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"E. S\u00f8fteland, J.J. Meier, B. Vangen, R. Toorawa, M. Maldonado-Lutomirsky, U.C. Broedl, Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care 40(2), 201\u2013209 (2017).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR107","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"A. Lewin, R.A. DeFronzo, S. Patel, D. Liu, R. Kaste, H.J. Woerle et al., Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38(3), 394\u2013402 (2015).","journal-title":"Diabetes Care"},{"issue":"11","key":"4393_CR108","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","volume":"15","author":"N Inagaki","year":"2014","unstructured":"N. Inagaki, K. Kondo, T. Yoshinari, N. Takahashi, Y. Susuta, H. Kuki, Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert. Opin. Pharmacother. 15(11), 1501\u20131515 (2014).","journal-title":"Expert. Opin. Pharmacother."},{"issue":"7","key":"4393_CR109","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"J. Rosenstock, M. Vico, L. Wei, A. Salsali, J.F. List, Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35(7), 1473\u20131478 (2012).","journal-title":"Diabetes Care"},{"issue":"6","key":"4393_CR110","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H.U. H\u00e4ring, L. Merker, E. Seewaldt-Becker, M. Weimer, T. Meinicke, U.C. Broedl et al., Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37(6), 1650\u20131659 (2014).","journal-title":"Diabetes Care"},{"issue":"3","key":"4393_CR111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali, U.C. Broedl et al., Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38(3), 420\u2013428 (2015).","journal-title":"Diabetes Care"},{"issue":"12","key":"4393_CR112","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"E. Ferrannini, A. Berk, S. Hantel, S. Pinnetti, T. Hach, H.J. Woerle et al., Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36(12), 4015\u20134021 (2013).","journal-title":"Diabetes Care"},{"issue":"11","key":"4393_CR113","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.clinthera.2017.10.003","volume":"39","author":"JF Yale","year":"2017","unstructured":"J.F. Yale, J. Xie, S.E. Sherman, C. Garceau, Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus. Clin. Ther. 39(11), 2230\u20132242.e2 (2017).","journal-title":"Clin. Ther."},{"issue":"8","key":"4393_CR114","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"C.S. Kovacs, V. Seshiah, L. Merker, A.V. Christiansen, F. Roux, A. Salsali et al., Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin. Ther. 37(8), 1773\u201388.e1 (2015).","journal-title":"Clin. Ther."},{"issue":"1","key":"4393_CR115","volume":"12","author":"L Cheng","year":"2022","unstructured":"L. Cheng, Q. Fu, L. Zhou, Y. Fan, F. Liu, Y. Fan et al., Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci. Rep. 12(1), 3525 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"4393_CR116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","volume":"110","author":"HU Haering","year":"2015","unstructured":"H.U. Haering, L. Merker, A.V. Christiansen, F. Roux, A. Salsali, G. Kim et al., Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 110(1), 82\u201390 (2015).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"11","key":"4393_CR117","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/dom.12737","volume":"18","author":"C Mathieu","year":"2016","unstructured":"C. Mathieu, M. Herrera Marmolejo, J.G. Gonz\u00e1lez Gonz\u00e1lez, L. Hansen, H. Chen, E. Johnsson et al., Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52\u2009weeks in patients with type 2 diabetes. Diabetes Obes. Metab. 18(11), 1134\u20131137 (2016).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"4393_CR118","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"A.H. Barnett, A. Mithal, J. Manassie, R. Jones, H. Rattunde, H.J. Woerle et al., Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2(5), 369\u2013384 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"4393_CR119","first-page":"54","volume":"1","author":"R Qiu","year":"2014","unstructured":"R. Qiu, G. Capuano, G. Meininger, Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J. Clin. Transl. Endocrinol. 1(2), 54\u201360 (2014).","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"1","key":"4393_CR120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"G. Grunberger, S. Camp, J. Johnson, S. Huyck, S.G. Terra, J.P. Mancuso et al., Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 9(1), 49\u201366 (2018).","journal-title":"Diabetes Ther."},{"key":"4393_CR121","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diabres.2017.06.018","volume":"130","author":"S Gadzhanova","year":"2017","unstructured":"S. Gadzhanova, N. Pratt, E. Roughead, Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res. Clin. Pract. 130, 180\u2013185 (2017).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"4393_CR122","volume":"13","author":"A Berhan","year":"2013","unstructured":"A. Berhan, A. Barker, Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr. Disord. 13, 58 (2013).","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"4393_CR123","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.13782","volume":"85","author":"S Adimadhyam","year":"2019","unstructured":"S. Adimadhyam, G.T. Schumock, G.S. Calip, D.E. Smith Marsh, B.T. Layden, T.A. Lee, Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. Br. J. Clin. Pharmacol. 85(1), 160\u2013168 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"4393_CR124","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, L. Li et al., Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85(5), 520\u2013526 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"4393_CR125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"K.M. Johnsson, A. Ptaszynska, B. Schmitz, J. Sugg, S.J. Parikh, J.F. List, Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J. Diabetes Complications 27(5), 479\u2013484 (2013).","journal-title":"J. Diabetes Complications"},{"issue":"8","key":"4393_CR126","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"M. Fusaroli, E. Raschi, E. Poluzzi, M. Hauben, The evolving role of disproportionality analysis in pharmacovigilance. Expert. Opin. Drug. Saf. 23(8), 981\u2013994 (2024).","journal-title":"Expert. Opin. Drug. Saf."},{"issue":"8","key":"4393_CR127","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1007\/s00277-024-05676-1","volume":"103","author":"MF Kt","year":"2024","unstructured":"M.F. Kt, M. Semwal, B.T. Yoosuf, D. Lad, D. Bansal, Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Ann. Hematol. 103(8), 3179\u20133191 (2024).","journal-title":"Ann. Hematol."},{"issue":"1","key":"4393_CR128","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83014-1","volume":"14","author":"M Favas Karimbanathottathil","year":"2024","unstructured":"M. Favas Karimbanathottathil, B.T. Yoosuf, M. Mamatha, D. Bansal, Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials. Sci. Rep. 14(1), 31859 (2024).","journal-title":"Sci. Rep."},{"key":"4393_CR129","doi-asserted-by":"publisher","unstructured":"B.T. Yoosuf, M. Favas Kt, P. Dutta, D. Bansal, Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms. Expert Opin. Drug Saf., 1\u201313 (2024). https:\/\/doi.org\/10.1080\/14740338.2024.2343015","DOI":"10.1080\/14740338.2024.2343015"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04393-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:08:22Z","timestamp":1761736102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04393-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4393"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04393-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,24]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}